Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer

Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV).

(2017) H. Hurwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

(2010) M. Reck et al.   ANNALS OF ONCOLOGY

Plasma Cytokine and Angiogenic Factor Profiling Identifies Markers Associated with Tumor Shrinkage in Early-Stage Non-Small Cell Lung Cancer Patients Treated with Pazopanib

(2010) P. G. Nikolinakos et al.   CANCER RESEARCH

Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non-Small Cell Lung Cancer Patients

(2010) P. M. Ellis et al.   CLINICAL CANCER RESEARCH

Phase II Proof-of-Concept Study of Pazopanib Monotherapy in Treatment-Naive Patients With Stage I/II Resectable Non–Small-Cell Lung Cancer

(2010) Nasser Altorki et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer

(2010) Giorgio Scagliotti et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Course of Advanced Non–Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4599

(2010) Suzanne E. Dahlberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

(2010) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and Safety of Oxaliplatin and Gemcitabine with Bevacizumab in Advanced Non-small Cell Lung Cancer

(2010) Rogerio Lilenbaum et al.   Journal of Thoracic Oncology

The Current Status and Evolving Role of Sunitinib in Non-small Cell Lung Cancer

(2010) Mark A. Socinski   Journal of Thoracic Oncology

The Tyrosine Kinase Inhibitor Cediranib for Non-small Cell Lung Cancer and Other Thoracic Malignancies

(2010) Petros Nikolinakos et al.   Journal of Thoracic Oncology

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell Lung Cancer

(2010) Craig Reynolds et al.   Journal of Thoracic Oncology

A Phase II First-Line Study of Gemcitabine, Carboplatin, and Bevacizumab in Advanced Stage Nonsquamous Non-small Cell Lung Cancer

(2010) Christelle Clément-Duchêne et al.   Journal of Thoracic Oncology

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

(2010) Roy S Herbst et al.   LANCET ONCOLOGY

Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study

(2010) Lucio Crinò et al.   LANCET ONCOLOGY

Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: A phase I dose-escalation study

(2010) Martin Reck et al.   LUNG CANCER

VEGF kinase inhibitors: how do they cause hypertension?

(2009) Pankaj Bhargava   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer

(2009) S Novello et al.   BRITISH JOURNAL OF CANCER

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study

(2009) Francisco Robert et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN™), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors

(2009) Noboru Yamamoto et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Treatment Rationale and Study Design for the PointBreak Study: A Randomized, Open-label Phase III Study of Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

(2009) Jyoti D. Patel et al.   Clinical Lung Cancer

Emerging Data with Antiangiogenic Therapies in Early and Advanced Non–Small-Cell Lung Cancer

(2009) Leora Horn et al.   Clinical Lung Cancer

Bevacizumab: current indications and future development for management of solid tumors

(2009) Jenia Jenab-Wolcott et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab With Maintenance Pemetrexed and Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer

(2009) Jyoti D. Patel et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

(2009) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety of Bevacizumab in Patients With Non–Small-Cell Lung Cancer and Brain Metastases

(2009) Mark A. Socinski et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and Safety of Axitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Phase II Study

(2009) Joan H. Schiller et al.   JOURNAL OF CLINICAL ONCOLOGY

Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study

(2009) Ronald B. Natale et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Non–Small-Cell Lung Cancer

(2009) George R. Blumenschein et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Pemetrexed Plus Bevacizumab for Second-Line Therapy of Patients With Advanced Non–Small-Cell Lung Cancer: NCCTG and SWOG Study N0426

(2009) Alex A. Adjei et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study

(2009) Glenwood D. Goss et al.   JOURNAL OF CLINICAL ONCOLOGY

An overview of small-molecule inhibitors of VEGFR signaling

(2009) S. Percy Ivy et al.   Nature Reviews Clinical Oncology

An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer

(2008) R. de Boer et al.   ANNALS OF ONCOLOGY

BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy

(2008) F. Hilberg et al.   CANCER RESEARCH

Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non-Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab--an Eastern Cooperative Oncology Group Study

(2008) A. Dowlati et al.   CLINICAL CANCER RESEARCH

A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel

(2008) K. T. Flaherty et al.   CLINICAL CANCER RESEARCH

A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group

(2008) Glenwood Goss et al.   EUROPEAN JOURNAL OF CANCER

Phase I and Pharmacokinetic Study of Daily Oral AZD2171, an Inhibitor of Vascular Endothelial Growth Factor Tyrosine Kinases, in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non–Small-Cell Lung Cancer: The National Cancer Institute of Canada Clinical Trials Group

(2008) Scott A. Laurie et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

(2008) John V. Heymach et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer

(2008) Mark A. Socinski et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase II Study of Oxaliplatin, Pemetrexed, and Bevacizumab in Previously Treated Advanced Non-small Cell Lung Cancer

(2008) Rebecca Suk Heist et al.   Journal of Thoracic Oncology

Outcomes for Elderly, Advanced-Stage Non–Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599

(2007) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY